Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) – Pipeline Review, H1 2017’, provides in depth analysis on Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4)Additionally, the report provides an overview of key players involved in Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Immunology, Cardiovascular, Central Nervous System, Genito Urinary System And Sex Hormones, Metabolic Disorders, Genetic Disorders, Ophthalmology and Respiratory under development targeting Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4)

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4)

The report reviews Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics and enlists all their major and minor projects

The report assesses Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Aptose Biosciences Inc

Arvinas Inc

AstraZeneca Plc

ConverGene LLC

Dybly AG

F. Hoffmann-La Roche Ltd

Forma Therapeutics Inc

GlaxoSmithKline Plc

Incyte Corp

Kainos Medicine Inc

Merck & Co Inc

Nuevolution AB

Plexxikon Inc

Resverlogix Corp

Trillium Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Overview

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Companies Involved in Therapeutics Development

Aptose Biosciences Inc

Arvinas Inc

AstraZeneca Plc

ConverGene LLC

Dybly AG

F. Hoffmann-La Roche Ltd

Forma Therapeutics Inc

GlaxoSmithKline Plc

Incyte Corp

Kainos Medicine Inc

Merck & Co Inc

Nuevolution AB

Plexxikon Inc

Resverlogix Corp

Trillium Therapeutics Inc

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Drug Profiles

apabetalone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARCC-29 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARV-763 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARV-771 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARV-825 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZD-5153 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

birabresib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CG-202 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CG-223 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CG-250 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CK-103 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CPI-0610 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DCBD-005 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DYB-186 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EP-11313 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FT-1101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-525762 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INCB-54329 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KM-601 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MA-2014 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MS-417 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MZ-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NEO-2734 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NUE-7770 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PLX-51107 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RG-6146 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RVX-2135 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-10 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SF-2523 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SF-2535 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Bromodomain Containing Protein-4 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit BRD4 and HDAC1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit BRD4 for Malignant Peripheral Nerve Sheath Tumors - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit BRD4 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit BRD4 for Ovarian Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SRX-3177 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TTI-281 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZBC-260 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZEN-3694 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Dormant Products

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Discontinued Products

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Product Development Milestones

Featured News & Press Releases

Jun 05, 2017: Resverlogix Announces Lead Drug Apabetalone Publication and Presentation at BIO International 2017

Jun 05, 2017: Zenith Announces Issuance of Patent for ZEN-3694 and Presentation Details at BIO International Convention

May 31, 2017: Resverlogix To Host Epigenetics Focused Symposium At The ERA-EDTA Congress in Madrid, Spain

May 30, 2017: Resverlogix Receives Approval From Health Canada To Proceed With Fabry Disease Clinical Trial With Lead Compound Apabetalone

May 23, 2017: Recent Publication and Patent Application Referencing Apabetalone Support its Continued Development and Success

May 15, 2017: Resverlogix Receives Approval From The FDA Cardiovascular and Renal Division To Proceed With A Requested Apabetalone Clinical Trial

May 01, 2017: SignalRx Discloses its Novel Immuno-Oncology Program Approach at the 12th Annual Drug Discovery Chemistry 2017 Meeting

Apr 25, 2017: SignalRx to Present at the 12th Annual Drug Discovery Chemistry 2017 Meeting on its First-In-Class Triple PI3K/CDK4-6/BRD4 Inhibitor SRX3177 for Treating Cancer

Apr 03, 2017: SignalRx to Present at the AACR Annual Meeting on its First-In-Class Triple PI3K/CDK4-6/BRD4 Inhibitor SRX3177 for Treating Cancer

Mar 17, 2017: Resverlogix Announces Third Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone and Provides an Update on Corporate Activities

Mar 15, 2017: Resverlogix Announces Receipt of Notice of Allowance from the United States Patent and Trademark Office

Feb 23, 2017: Resverlogix Reports Positive FDA Type B Meeting on Design Issues Relating to a Proposed Phase 2a Kidney Dialysis Trial

Feb 13, 2017: Resverlogix Highlights Unique Properties of Apabetalone in Both a Rare Muscular Dystrophy and Neurodegenerative Eye Disease

Feb 01, 2017: SignalRx Pharmaceuticals Announces Breakthrough Results on Novel Anti-Cancer Dual PI3K-BRD4 Inhibition Paradigm in PNAS Publication

Jan 23, 2017: Resverlogix Provides Groundbreaking Results in Patients with Severe Kidney Impairments

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Indications, H1 2017

Number of Products under Development by Indications, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Indications, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1)

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Number of Products under Investigation by Universities/Institutes, H1 2017

Products under Investigation by Universities/Institutes, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Pipeline by Aptose Biosciences Inc, H1 2017

Pipeline by Arvinas Inc, H1 2017

Pipeline by AstraZeneca Plc, H1 2017

Pipeline by ConverGene LLC, H1 2017

Pipeline by Dybly AG, H1 2017

Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Pipeline by Forma Therapeutics Inc, H1 2017

Pipeline by GlaxoSmithKline Plc, H1 2017

Pipeline by Incyte Corp, H1 2017

Pipeline by Kainos Medicine Inc, H1 2017

Pipeline by Merck & Co Inc, H1 2017

Pipeline by Nuevolution AB, H1 2017

Pipeline by Plexxikon Inc, H1 2017

Pipeline by Resverlogix Corp, H1 2017

Pipeline by Trillium Therapeutics Inc, H1 2017

Dormant Projects, H1 2017

Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Top 10 Indications, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports